[New aspects of macrolides: contribution of roxithromycin].
Roxithromycin (RU 28965) is a new semi-synthetic derivative of erythromycin. Its antibacterial activity is of the same order as that of other macrolides, although its MIC's against Legionella pneumophila are lower. In double-blind comparative studies there was no significant difference in therapeutic effectiveness between roxithromycin and the reference antibiotics tested. However, this new macrolide exhibits exceptional pharmacological properties (prolonged half-life, excellent tissue penetration and intracellular activity), and it is very well tolerated both clinically and biochemically.
Bertrand
A
A
Clinique des maladies infectieuses A, Montpellier.
Jonquet
O
O
D001424:Bacterial Infections / Q000188:drug therapy*; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D007933:Leucomycins / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*
D007933:Leucomycins
Aspects nouveaux des macrolides: apport de la roxithromycine.